Risks

High net debt to EBITDA and zero reported current and quick ratios increase refinancing sensitivity versus better-capitalized peers, constraining flexibility if operating conditions soften.

Interest coverage above 8x supports near-term servicing, but leverage remains elevated versus most specialty pharma peers, leaving less room for earnings volatility.

A 49-day cash conversion cycle ties up working capital, which can pressure liquidity more than peers with faster collections and inventory turns.

Limited disclosed liquidity metrics reduce visibility on near-term balance-sheet resilience, making FCRX more exposed than peers with stronger cash buffers and broader funding access.

Opportunities

Interest coverage above 8x indicates current earnings can service debt, giving FCRX more operating headroom than highly stressed peers if demand remains stable.

If cash generation improves, elevated leverage can delever quickly from a smaller base, creating more upside to equity value than for less levered peers.

Working-capital normalization from the 49-day cash conversion cycle could release cash, improving liquidity and reducing dependence on external financing versus peers with slower conversion.

A manageable servicing burden relative to debt size may support continued commercial execution, while weaker peers face greater distraction from balance-sheet stress.

Overall Score

FCRX faces meaningful balance-sheet and liquidity risk versus peers, but current interest coverage and potential working-capital improvement provide some offsetting upside.